Evidence for an ALS Survival Benefit with CNM-Au8 Treatment: Interim Results from the RESCUE-ALS Trial Long-Term Open Label Extension All Randomized All OLE Participants (CNM-Au8 Treated) All CNM-Au8 Randomized All Placebo Randomized CNM-Au8 OLE ex-Placebo to CNM-Au8 OLE Survival by OLE Status Notes: All randomized subjects including study withdrawals. Data censored for all subjects of 1-February-2022. Vital status and date of death captured for all subjects withdrawn from the study through Dec 2021. Lost-to-follow-up (n=1) censored as of the last date of last study contact. ENCALS median survival estimate from baseline characteristics.  Steve Vucic PhD, DSc, FRACP, FAHMS1, Parvathi Menon PhD, FRACP1, William Huynh PhD, FRACP2, Colin Mahoney, PhD, MB, MRCPI2, Karen S. Ho, PhD MSc3, Austin Rynders, RN3, Jacob Evan3, Jeremy Evan, PA-C3, Robert Glanzman, MD FAAN3, Michael T. Hotchkin3, Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS 1Concord Repatriation General Hospital, University of Sydney, Australia; 2Brain and Mind Centre, University of Sydney, Australia; 3Clene Nanomedicine, Salt Lake City, UT, USA Acknowledgements: We thank the ALS study patients and their families for their support and willingness to engage in clinical research. We thank the site investigators for their research excellence and dedication to patients. We thank FightMND of Australia for substantially funding the RESCUE-ALS trial. Exhibit 99.3